TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Nordic Drugs AB
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
374,683
|
341,924
|
283,846 |
| Financial expenses |
1,481
|
14
|
71 |
| Earnings before taxes |
39,109
|
15,098
|
-2,810 |
| EBITDA |
39,359
|
14,284
|
-3,711 |
| Total assets |
191,989
|
172,397
|
131,575 |
| Current assets |
191,444
|
171,281
|
129,294 |
| Current liabilities |
57,185
|
68,319
|
43,433 |
| Equity capital |
131,418
|
99,176
|
83,587 |
| - share capital |
20,626
|
20,261
|
18,918 |
| Employees (average) |
25
|
25
|
26 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
68.5%
|
57.5%
|
63.5% |
| Turnover per employee |
14,987
|
13,677
|
10,917 |
| Profit as a percentage of turnover |
10.4%
|
4.4%
|
-1.0% |
| Return on assets (ROA) |
21.1%
|
8.8%
|
-2.1% |
| Current ratio |
334.8%
|
250.7%
|
297.7% |
| Return on equity (ROE) |
29.8%
|
15.2%
|
-3.4% |
| Change turnover |
26,594
|
37,937
|
56,788 |
| Change turnover % |
8%
|
12%
|
25% |
| Chg. No. of employees |
0
|
-1
|
0 |
| Chg. No. of employees % |
0%
|
-4%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.